Test Price
2,800 AED✅ Home Collection Available
SLC26A5 Gene Deafness, Autosomal Recessive Type 61 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189‑accredited NGS processing with secondary confirmation.
Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Home Collection and VIP Mobile Phlebotomy (8 AM‑11 PM).
Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation with a DHA‑licensed genetic counsellor.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This DNA test screens the SLC26A5 gene for variants causing autosomal recessive deafness type 61 (DFNB61), a form of congenital/prelingual sensorineural hearing loss. The assay uses next-generation sequencing (NGS) to cover the entire coding region, splice sites, and selected intronic regions, combined with deletion/duplication analysis for comprehensive diagnostic yield.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Methodology | NGS (full gene sequencing) + deletion/duplication analysis | Single‑gene Sanger sequencing (misses deep intronic/copy‑number variants) |
| Diagnostic Rate | >95% for DFNB61‑related variants | ~80% (limited coverage) |
| Turnaround Time | 3‑4 weeks (routine) | 6‑8 weeks |
| Sample Types | Whole blood, extracted DNA, or one‑drop blood on FTA card | Whole blood only |
Physician Insight & Safety Protocols
"Every genetic result must be interpreted within the patient’s full audiological and family history. A positive SLC26A5 variant confirms the molecular diagnosis, but clinical correlation with pure‑tone audiometry, ABR, and imaging remains essential. I always remind families that carrier status alone does not predict hearing outcome and that cochlear implantation or early intervention can still be life‑changing."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Advisory & Exclusion Criteria
Clinical Precautions
- Medication Warning: Do not discontinue any prescribed medication before, during, or after this genetic test without direct consultation with your treating physician.
- Exclusion criteria: Active infection at the phlebotomy site; inability to provide informed consent (minors require guardian consent per UAE law); recent blood transfusion (<2 weeks) may affect test quality.
- ER Red Flags: If the patient experiences sudden worsening of hearing, vertigo, or neurological signs (facial weakness, ataxia) while awaiting results, seek immediate emergency care — these symptoms are not attributable to the test and require urgent evaluation.
Patient FAQ & Clinical Guidance
1. What does a positive SLC26A5 gene test mean for my child's hearing?
A positive result identifies two pathogenic variants (one from each parent) confirming autosomal recessive deafness type 61, which causes non‑syndromic sensorineural hearing loss usually present at birth. Early diagnosis allows timely intervention including hearing aids or cochlear implants.
2. Is this test covered by insurance in the UAE?
Many UAE insurers now cover medically indicated genetic testing when accompanied by a referral from an ENT or clinical geneticist; our team verifies coverage within hours via WhatsApp +971 54 548 8731 before collection.
3. Can I use a dried blood spot (FTA card) instead of a blood draw?
Yes, a single drop of blood on an FTA card is fully validated for this NGS test, making it ideal for infants, remote home collection, and rapid transport. Our mobile phlebotomy team can collect this sample at your home or office.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic data is processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and confidentiality are strictly enforced. Clinical safety follows Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory is ISO 15189 accredited and data is stored on ISO 27001 certified servers within UAE borders.
Clinical & Logistical Metadata
| Test Name | SLC26A5 Gene Deafness, Autosomal Recessive Type 61 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (routine) |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card (dried blood spot) |
| Methodology Used | Next-Generation Sequencing (whole gene + deletion/duplication analysis) |
| ICD-10-CM Code | H90.3, H90.5, Z14.8 |
| LOINC Code | 93428-1 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians